Global Plasma Fractionation Market

Plasma Fractionation Market Size, Share, Growth Analysis, By Product (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Other Plasma Products), By Method (Cryoprecipitation, Chromatography, Ethanol Precipitation, Ultrafiltration, Others), By End Use, By Region -Industry Forecast 2026-2033

Report ID: SQMIG35H2165 | Region: Global | Published Date: August, 2025
Pages: 173 |Tables: 94 |Figures: 68

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Plasma Fractionation Market size was valued at USD 36.2 Billion in 2024 and is poised to grow from USD 39.2 Billion in 2025 to USD 74.19 Billion by 2033, growing at a CAGR of 8.3% in the forecast period (2026–2033).

    The competitive landscape of the global plasma fractionation industry remains dynamic and innovation-driven, with leading players focusing on strategic collaborations, capacity expansions, and regional ecosystem development to meet the surging global demand for plasma-derived therapies. Major companies such as Grifols, Takeda, CSL Behring, and Octapharma continue to dominate the landscape by investing in new manufacturing infrastructure and expanding their plasma collection networks. 'Grifols, S.A.', 'Takeda Pharmaceutical Company Limited', 'CSL Behring', 'Octapharma AG', 'Kedrion S.p.A.', 'Bio Products Laboratory Ltd (BPL)', 'Bharat Serums and Vaccines Limited', 'GC Biopharma Corp.', 'LFB S.A.', 'Sanquin', 'Shanghai RAAS Blood Products Co., Ltd.', 'China Biologic Products Holdings, Inc.'

    The increasing global burden of chronic conditions such as primary immunodeficiency, hemophilia, and autoimmune diseases is a major driver for the plasma fractionation market. These disorders require long-term administration of plasma-derived therapies like immunoglobulins and coagulation factors. With a growing elderly population and higher diagnostic awareness, demand for these treatments continues to expand.

    Integration of Artificial Intelligence in Process Automation: A transformative market trend in the plasma fractionation industry is the adoption of AI and machine learning to enhance efficiency and accuracy. AI-powered systems are now being used for real-time process monitoring, predictive yield estimation, and automated equipment maintenance scheduling. In 2024, companies began deploying AI platforms to analyze thousands of batch data points, ensuring early detection of anomalies and improving consistency across production cycles. This has led to higher product yields, lower wastage, and improved safety outcomes. As regulatory bodies grow more receptive to digital validation, AI is expected to become a standard in plasma fractionation plants worldwide.

    How is the Plasma Fractionation Market Evolving in North America?

    Related Reports

    Plasma Therapy Market
    Buy Now GET FREE SAMPLE
    Plasmapheresis Market
    Buy Now GET FREE SAMPLE
    Cold Plasma Market
    Buy Now GET FREE SAMPLE
    Platelet Rich Plasma Market
    Buy Now GET FREE SAMPLE
    Helium Market
    Buy Now GET FREE SAMPLE
    GCC Plasma Welding Machine Market
    Buy Now GET FREE SAMPLE
    Potassium Formate Market
    Buy Now GET FREE SAMPLE
    Pulse Oximeters Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Plasma Fractionation Market

    Report ID: SQMIG35H2165

    $5,300
    BUY NOW